


A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions

Washington State Transactions by Industry



2016 Highlights

2016 Highlights

75 companies made 104 deals, 40% of which were in the biotechnology subsector

- Investments in **medical technologies** were up 4.45x from 2013, 2.2x from 2015
- Investments in **pharmaceuticals** and **digital health/HIT** were down from 2013 and 2015
- 2017 Trends to Watch:** Immunotherapies, CAR-T therapies and rare disease biologics

Pharmaceuticals

Top 5 Deals:

- Juno Therapeutics** \$50M (Partnership | Celgene)
- Alpine Immune Sciences** \$48M (Equity)
- Aptevo Therapeutics** \$35M (Debt)
- Cytodyn** \$30.57M (Equity)
- Immune Design** \$30.3M (Public Offering)

Medical Technology

Top 5 Deals:

- Physio-Control** \$1.28B (Acquisition | Stryker)
- NanoString Technologies** \$24M (Partnership | Merck)
- Impel Neuropharma** \$22.2M (Series C)
- NanoString Technologies** \$22M (unknown)
- C3J Therapeutics** \$18.99M (Equity)

Digital Health/ Health IT

Top 5 Deals:

- Medstreaming LLC** \$12.2M (Equity)
- 98point6** \$11M (Equity)
- Valant Medical Solutions** \$7.5M (Equity)
- CSATS** \$3.28M (Equity)
- Medstreaming LLC** \$2.5M (Equity)

Washington Life Science Transactions 2016

Date	Company	Type	Amount	Date	Company	Type	Amount
01/07/16	NanoString Technologies	Unknown	\$22,000,000	06/13/16	Alpine Immune Sciences	Equity	\$48,000,000
01/11/16	Spiral Genetics	Unknown	\$50,000	06/20/16	Kineta	Debt	\$1,752,688
01/12/16	Blaze Bioscience	Debt	\$991,000	06/22/16	Marina Biotech	Debt	\$300,000
01/14/16	Stemgenics	Equity	\$930,000	06/24/16	TwinStrand Biosciences	Debt	\$1,938,964
01/20/16	Vicis	Seed	\$8,000,000	07/05/16	Revalerio Corp	Equity	\$13,999,912
01/25/16	Clario Medical Imaging	Equity	\$185,000	07/14/16	Magnolia Medical Technologies	Series B	\$13,757,109
02/02/16	Oricula Therapeutics	Grant	\$2,060,000	07/19/16	Joylux	Equity	\$2,000,000
02/02/16	ID Genomics	Equity	\$50,000	07/26/16	Just Biotherapeutics	Series A	\$14,000,000
02/11/16	M3 Biotechnology	Equity	\$10,000,000	08/04/16	98point6	Equity	\$11,000,000
02/11/16	Spiral Genetics	Unknown	\$50,000	08/05/16	Mirabilis Medica	Debt	\$5,000,000
02/16/16	Physio-Control	Acquisition	\$1,280,000,000	08/05/16	Aptevo Therapeutics	Debt	\$35,000,000
02/16/16	KPI Therapeutics	Debt	\$50,500	08/09/16	CSATS	Equity	\$3,283,516
02/17/16	Glycostasis	Acquisition	undisclosed	08/09/16	SpringStar	Grant	\$1,500,000
02/23/16	Cytodyn	Equity	\$30,574,665	08/10/16	Ave Maria Biotechnology	Equity	\$100,000
02/24/16	Ave Maria Biotechnology	Equity	\$40,000	08/17/16	Kineta IO, LLC	Equity	\$238,422
02/29/16	VitalWare	Series A	undisclosed	08/17/16	Kineta One, LLC	Debt	\$125,000
02/29/16	NanoString Technologies	Partnership	\$24,000,000	08/17/16	Vie Diagnostics	Grant	\$225,000
03/03/16	LabConnect	Venture Equity	\$4,000,000	08/19/16	Nexgenia	Equity	\$1,859,887
03/11/16	Allen Institute for Brain Science	Contract	\$18,700,000	08/23/16	Benaroya Research Institute	Grant	\$8,000,000
03/16/16	Ave Maria Biotechnology	Equity	\$350,000	08/24/16	Briotech	Equity	\$250,000
03/17/16	Act X	Unknown	\$308,810	08/29/16	Impel Neuropharma	Debt	\$1,090,000
03/22/16	Seattle Children's Research Institute	Grant	\$1,000,000	08/29/16	Navisonics	Debt	\$335,000
03/22/16	Breast Microseed	Debt	\$100,000	08/30/16	KinDex Pharmaceuticals	Debt	\$327,274
03/23/16	Frazier Healthcare Partners	Fund	\$525,000,000	09/16/16	Sound Pharmaceuticals	Debt	\$3,800,000
03/23/16	University of Washington	Grant	\$250,000	09/16/16	Cocrystal Discovery	Equity	\$4,008,201
03/24/16	The Paul G. Allen Frontiers Group	Fund	\$100,000,000	09/20/16	Immune Design	Public Offering	\$30,300,000
04/06/16	Cyrus Biotechnology	Debt	\$535,000	09/26/16	Ario	Equity	\$1,035,000
04/06/16	2Morrow	Debt	\$325,000	09/28/16	Verda Bio	Equity	\$545,000
04/07/16	Medstreaming LLC	Equity	\$12,200,000	09/29/16	PotaVida	Equity	\$275,000
04/07/16	Prevencio, Inc	Debt	\$675,000	10/06/16	Infectious Disease Research Institute	Grant	\$491,000
04/08/16	Medstreaming LLC	Equity	\$2,500,000	10/13/16	Feminina Group	Debt	\$77,500
04/12/16	Silverback Therapeutics	Equity	\$10,000,000	10/13/16	Vicis	Debt	\$3,955,000
04/14/16	Vicis	Series A	\$4,000,000	10/18/16	Impel Neuropharma	Debt	\$80,000
04/18/16	Juno Therapeutics	Partnership	\$50,000,000	10/18/16	Sightlight Surgical	Series A	\$10,000,000
04/23/16	ID Genomics	Grant	\$3,000,000	10/18/16	Infectious Disease Research Institute	Partnership	\$15,000,000
04/27/16	Cardiac Insight	Debt	\$2,505,524	10/31/16	Deep Cell Industries	Equity	\$25,000
04/29/16	Ave Maria Biotechnology	Equity	\$2,200,000	11/01/16	ImmuSoft Corp	Series A	\$2,739,999
05/05/16	Kineta	Award	\$7,200,000	11/07/16	Act X	Equity	\$1,900,646
05/10/16	Aqueduct Critical Care	Equity	\$3,067,177	11/16/16	Cyrus Biotechnology	Equity	\$490,000
05/10/16	Spiral Genetics	Unknown	\$50,000	11/18/16	Invio, Inc	Angel	\$160,000
05/11/16	Cytodyn	Equity	\$4,301,500	12/01/16	Washington State University	Grant	\$50,000
05/11/16	Mental Health Data Services	Equity	\$333,333	12/01/16	Impel Neuropharma	Series C	\$22,297,064
05/13/16	Ave Maria Biotechnology	Equity	\$50,000	12/05/16	Nohla Therapeutics	Series A	\$11,999,999
05/17/16	PhaseRx	IPO	\$18,500,000	12/05/16	KPI Therapeutics	Equity	\$18,000
05/20/16	Haverhill Genetics	Debt	\$125,000	12/06/16	Cardiac Insight	Series C	\$1,000,000
05/24/16	Vicis	Equity	\$6,000,000	12/08/16	ApoGen Biotechnologies, Inc	Series A	\$3,815,892
05/25/16	Kineta Three, LLC	Equity	\$760,778	12/08/16	Integrated Diagnostics	Equity	\$6,099,999
05/26/16	Litesprite	Debt	\$50,000	12/13/16	Ave Maria Biotechnology	Equity	\$225,000
05/31/16	Kineta Two, LLC	Equity	\$67,275	12/20/16	Briotech	Equity	\$100,000
06/02/16	Mirabilis Medica	Debt	\$2,232,833	12/21/16	C3I Therapeutics	Equity	\$18,999,999
06/09/16	Ave Maria Biotechnology	Equity	\$100,000	12/28/16	Valant Medical Solutions	Equity	\$7,500,000
06/09/16	Cadence Biomedical	Debt	\$80,000				
				2016 Total			\$2,470,649,466

Don't see a transaction listed?

Contact Kayla Young at

kayla@lifesciencewa.org

This report is prepared by Wendy Yang, PhD, and Kayla Young, PhD. Questions or comments? Contact kayla@lifesciencewa.org.

***The data in this report are compiled from publicly disclosed information and is not independently verified by Life Science Washington.*